AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.
In the realm of healthcare stocks, AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) present compelling options for investors looking ahead to 2026. AbbVie has made a strategic shift away from its dependence on a single blockbuster drug to a more diversified approach, focusing on immunology and aesthetics. This pivot aims to scale newer blockbuster treatments to replace older ones, with the majority of its domestic pharmaceutical sales flowing through major wholesalers and government agencies, such as McKesson (NYSE:MCK), Cardinal Health (NYSE:CAH), and Cencora (NYSE:COR).
Bristol Myers Squibb, meanwhile, continues to be a leader in oncology and cardiovascular health, investing in the rejuvenation of its portfolio following significant acquisitions. The two companies cater to dividend seekers, but their divergent futures in earnings estimates create a distinct choice for investors. AbbVie's growth hinges on successfully introducing new treatments and maintaining strong sales to large distributors, while Bristol Myers Squibb's prospects rest on refreshing its offerings and sustaining leadership in its key market segments.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
